Georgia Medicaid Now Covers TheraSkin®. Decision Benefits Medicaid Patients with Chronic Wounds
NEWPORT NEWS, Virginia (December 1, 2014) – The Georgia Department of Community Health (Medicaid) has provided coverage for TheraSkin®, a real skin therapy that effectively treats chronic wounds. The DCH is dedicated to “A Healthy Georgia”, with a key goal of “Increasing effectiveness and efficiency in the delivery of health care programs.” TheraSkin, a clinically and cost effective product, is a step to a more Healthy Georgia.
“We applaud the decision by the Georgia DCH to cover this limb and life-saving product for their 1.2 Million Medicaid recipients,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Georgia residents with diabetic and venous leg ulcers will now have access to clinically and cost-effective living cell therapy. Living cell therapy has been cited as the new standard of care for these types of ulcers.
Patients who will particularly benefit from the wound healing capabilities of TheraSkin are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.
About 25% of Georgians over 65 have diabetes. Georgia spends $3.2 Billion every year on diabetes care. “We will work tirelessly with the medical institutions and practitioners in Georgia to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.
TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. It’s fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. TheraSkin costs less per application than other living cell therapies and requires, on average, fewer applications to heal chronic wounds.
Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.
For more information on Georgia Medicaid coverage, please go to https://www.mmis.georgia.gov/portal/PubAccess.Provider%20Information/Fee%20Schedules/tabId/56/Default.aspx. TheraSkin code on the fee schedule is Q4121.